Date
of report (Date of earliest event reported)
|
November
19, 2008
|
NANOVIRICIDES,
INC.
|
(Exact
Name of Registrant as Specified in Its
Charter)
|
Nevada
|
000-1379006
|
76-0674577
|
(State
or Other Jurisdiction of Incorporation)
|
(Commission
File Number)
|
(I.R.S.
Employer Identification No.)
|
135
Wood Street, Suite 205
West
Haven, Connecticut
|
06516
|
|
(Address
of Principal Executive Offices)
|
(Zip
Code)
|
(203)
937-6137
|
(Registrant's
Telephone Number, Including Area
Code)
|
¨
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
|
¨
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
¨
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
|
¨
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
|
Item 7.01.
|
Regulation FD
Disclosure
|
Item 9.01
|
Financial Statements and
Exhibits.
|
|
(d)
|
Exhibits
|
Exhibit
#
|
Description
|
|
99.1
|
Transcript
of Interview of Eugene Seymour,
MD
|
NANOVIRICIDES,
INC.
|
|||
Date:
November 19, 2008
|
By:
|
/s/
Dr. Eugene Seymour
|
|
Dr.
Eugene Seymour
|
|||
Chief
Executive Officer
|
Exhibit
#
|
Description
|
|
Transcript
of Interview of Eugene Seymour,
MD
|